Endogenex, a company focused on developing medical devices for type 2 diabetes management, has shared results from its REGENT-1 clinical study during the Digestive Disease Week (DDW) 2025 event held ...

MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE)-- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), announced the publication ...

MINNEAPOLIS, June 17, 2025 (GLOBE NEWSWIRE) -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), will present results from ...

MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Endogenex, a clinical-stage medical technology company pioneering a new treatment for type 2 diabetes (T2D), today announced the closing of a $50 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Plymouth, Minnesota-based ...

Bringing finance, operational, and corporate development expertise to an experienced leadership team. MINNEAPOLIS, Jan. 15, 2025 /PRNewswire/ --Endogenex, Inc., a clinical-stage medical device company ...

MINNEAPOLIS, May 03, 2025 (GLOBE NEWSWIRE) -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), presented significant ...

MINNEAPOLIS, June 25, 2024 /PRNewswire/ -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes, announced it has closed an ...

Novel Endoscopic Procedure Demonstrates Substantial and Durable Reduction in Insulin Resistance and Improvement in Beta Cell Function for People with Type 2 Diabetes MINNEAPOLIS, May 03, 2025 (GLOBE ...

(MENAFN- GlobeNewsWire - Nasdaq) Arboretum Ventures leads financing, with participation from existing investors, as Endogenex advances its novel treatment targeting a damaged duodenum as a driver of ...